3 Unprofitable Stocks We Think Twice About

Barchart·04/14/2026 02:00:30

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

A lack of profits can lead to trouble, but StockStory helps you identify the businesses that stand a chance of making it through. Keeping that in mind, here are three unprofitable companiesthat don’t make the cut and some better opportunities instead.

Albany (AIN)

Trailing 12-Month GAAP Operating Margin: -2.2%

Founded in 1895, Albany (NYSE:AIN) is a global textiles and materials processing company, specializing in machine clothing for paper mills and engineered composite structures for aerospace and other industries.

Why Do We Avoid AIN?

1. 1.5% annual revenue growth over the last two years was slower than its industrials peers
2. 10.7 percentage point decline in its free cash flow margin over the last five years reflects the company’s increased investments to defend its market position
3. Waning returns on capital from an already weak starting point displays the inefficacy of management’s past and current investment decisions

Albany is trading at $57.90 per share, or 23.7x forward P/E. Check out our free in-depth research report to learn more about why AIN doesn’t pass our bar.

Strategy (MSTR)

Trailing 12-Month GAAP Operating Margin: -1,141%

Once a traditional business intelligence software provider, Strategy (NASDAQ:MSTR) develops AI-powered enterprise analytics software while also functioning as a major corporate holder of Bitcoin cryptocurrency.

Why Is MSTR Risky?

1. MicroStrategy’s core analytics software has been eclipsed by its all-in Bitcoin strategy, leaving product innovation and enterprise deals starved for attention
2. The company’s debt-financed Bitcoin buying ties shareholder fortunes to crypto swings and interest rates, amplifying downside risk and uncertainty
3. On the bright side, its vast Bitcoin treasury gives Executive Chairman Michael Saylor a unique springboard to capture crypto upside and court investors seeking leveraged exposure to digital assets

At $134.85 per share, Strategy trades at 76.4x forward price-to-sales. Read our free research report to see why you should think twice about including MSTR in your portfolio.

Supernus Pharmaceuticals (SUPN)

Trailing 12-Month GAAP Operating Margin: -8.7%

With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.

Why Are We Cautious About SUPN?

1. Annual revenue growth of 5.6% over the last five years was below our standards for the healthcare sector
2. Revenue base of $717.2 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale
3. Free cash flow margin dropped by 14.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up

Supernus Pharmaceuticals’s stock price of $49.90 implies a valuation ratio of 21.5x forward P/E. Dive into our free research report to see why there are better opportunities than SUPN.

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.